We’re sorry, we weren’t able to find any data.
Please try reloading the page.
Trading Information
Stock Price History
Beta (5Y Monthly)
2.49
52-Week Change3
N/A
S&P500 52-Week Change3
N/A
52 Week High3
1.0650
52 Week Low3
0.0510
50-Day Moving Average3
0.0745
200-Day Moving Average3
0.2647
Share Statistics
Avg Vol (3 month)3
426.44k
Avg Vol (10 day)3
579.52k
Shares Outstanding5
136.18M
Implied Shares Outstanding6
N/A
Float8
76.9M
% Held by Insiders1
47.72%
% Held by Institutions1
0.00%
Shares Short 4
N/A
Short Ratio 4
N/A
Short % of Float 4
N/A
Short % of Shares Outstanding 4
N/A
Shares Short (prior month )4
N/A
Dividends & Splits
Forward Annual Dividend Rate4
N/A
Forward Annual Dividend Yield4
N/A
Trailing Annual Dividend Rate3
N/A
Trailing Annual Dividend Yield3
N/A
5 Year Average Dividend Yield4
N/A
Payout Ratio4
0.00%
Dividend Date3
N/A
Ex-Dividend Date4
N/A
Last Split Factor2
N/A
Last Split Date3
N/A
Financial Highlights
Fiscal Year
Fiscal Year Ends
Dec 30, 2021
Most Recent Quarter (mrq)
Dec 30, 2021
Profitability
Profit Margin
0.00%
Operating Margin (ttm)
-13,246.03%
Management Effectiveness
Return on Assets (ttm)
-60.17%
Return on Equity (ttm)
N/A
Income Statement
Revenue (ttm)
60.46k
Revenue Per Share (ttm)
0.00
Quarterly Revenue Growth (yoy)
N/A
Gross Profit (ttm)
60.46k
EBITDA
-5.89M
Net Income Avi to Common (ttm)
-16.02M
Diluted EPS (ttm)
-0.0810
Quarterly Earnings Growth (yoy)
N/A
Balance Sheet
Total Cash (mrq)
452.96k
Total Cash Per Share (mrq)
0
Total Debt (mrq)
6.75M
Total Debt/Equity (mrq)
N/A
Current Ratio (mrq)
0.25
Book Value Per Share (mrq)
0.03
Cash Flow Statement
Operating Cash Flow (ttm)
-2.49M
Levered Free Cash Flow (ttm)
511.89k
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.
SAN DIEGO, May 24, 2022 -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed the optimization of a rapid diagnostics test for the quantitative measurement of Ocular Immuno... Read More...
SAN DIEGO, April 27, 2022 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a rapid quantitative tear test for Lacritin, a tear protein that autonomously promotes tearing ... Read More...
Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic systemPlans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED management teamSupply agreements in place to fulfill demand for DED readers and tes... Read More...
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab Testing Exec Barry CraigAXIM develops and files for a patent for Novel Tear Collector System SAN DIEGO, Feb. 15, 2022 -- AXIM Biotechnologies,... Read More...
SAN DIEGO, Dec. 21, 2021 -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics, oncological research, and dry eye disease, announced today that the Centers for Disease Control and Prevention (CDC) highlighted a study that the Compa... Read More...
SAN DIEGO, Nov. 18, 2021 -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today applauds the FDA on its recent update to its COVID-19 test policies that aims to increase nationwide access to ... Read More...
SAN DIEGO, Nov. 02, 2021 -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today announced it has appointed Michael E. Stern, MS, Ph.D., to its Medical Advisory Board. He joins AXIM’s four oth... Read More...
SAN DIEGO, Oct. 20, 2021 -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced it has appointed Kelly K. Nichols, O.D., M.P.H., Ph.D. to its Medical Advisory Board. Dr. Nichols joi... Read More...
SAN DIEGO, Oct. 11, 2021 -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced it has appointed Henry D. Perry, MD to its recently established Medical Advisory Board. He is the thi... Read More...
SAN DIEGO, Sept. 15, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19, dry eye disease (DED) and Cancer, today announced that it has appointed Jeffrey A. Busby to Senior Vice President – Business Development. Mr. Busby brings more t... Read More...
SAN DIEGO, Aug. 30, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease diagnostics, announced today that the Company’s manufacturing partner Empowered Diagnostics has filed an amended emergency use a... Read More...
SAN DIEGO, May 03, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today a new ELISA test that measures levels of neutralizing antibodies against six common variants of SARS-CoV-2 virus. The Co... Read More...
